Administration of a phorbol ester to patients with hematological malignancies: Preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2512-2518

  Strair, Roger K ^a   Schaar, Dale ^a   Goodell, Lauri ^a   Aisner, Joseph ^a   Chin, Khew Voon ^a   Eid, Joseph ^a   Senzon, Rachelle ^a   Cui, Xiao Xing ^a   Han, Zheng Tao ^a   Knox, Beth ^a   Rabson, Arnold B ^a   Chang, Richard ^a   Conney, Allan ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHORBOL 13 ACETATE 12 MYRISTATE; PHORBOL ESTER; COMPLEMENTARY DNA;

ADULT; AGED; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CHINA; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HEMATOPOIETIC CELL; HUMAN; MALE; MYELOID LEUKEMIA; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; UNITED STATES; BLOOD DISEASE; CELL CULTURE; CELL STRAIN HL 60; DNA MICROARRAY; IMMUNOPHENOTYPING; METABOLISM; MIDDLE AGED; TIME;

ADULT; AGED; CELLS, CULTURED; DNA, COMPLEMENTARY; FEMALE; HEMATOLOGIC NEOPLASMS; HL-60 CELLS; HUMAN; IMMUNOPHENOTYPING; MALE; MIDDLE AGE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; HUMANS; MIDDLE AGED;

EID: 0036023408     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Systemic promoting action of phorbol in liver and lung carcinogenesis in AKR mice
2. Phorbol-ester tumor promoting agents and membrane stability
3. The effects of phorbole ester promoters on the basal and catecholamine-stimulated levels of cAMP in mouse skin and epidermis in vivo
4. Regulation of ornithine decarboxylase gene expression in mouse epidermis and epidermal tumors during two-stage tumorigenesis
5. 1 α, 25-dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin
6. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor promoting agents
7. Regulation of differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion
8. Human promyelocytic cells in culture differentiate into macrophage-like cells when treated with a phorbol diester
9. Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia
10. The potential for isoenzyme-selective modulation of protein kinase C
11. Modulating protein kinase C signal transduction
12. Protein kinase C: Structure, function, and regulation
13. Eyes wide shut: Protein kinase C isoenzymes are not the only receptors for the phorbol ester tumor promoters
14. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase/mitogen activated protein kinase signal transduction pathway: Potential role in promoting cytotoxic drug action
15. Kinases: Positive and negative regulators of apoptosis
16. Mammalian MAP kinase signalling cascades
17. Pharmacologic regulation of network kinetics by protein kinase C localization
18. Anchoring proteins for protein kinase C: A means for isozyme specificity
19. Activation of protein kinase C subtypes α, γ, δ, ε, ζ, and η by tumor-promoting and nontumor-promoting agents
20. Signaling 2000 and beyond
21. The search for physiological substrates of MAP and SAP kinases in mammalian cells
22. Organization and regulation of MAPK signaling pathways
23. Signal transduction: Hanging on a scaffold
24. Increasing complexity of the ras signaling pathway
25. Serine/threonine phosphorylation in cytokine signal transduction
26. Direction of p21 ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2
27. Human IL-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells
28. Specific activation of p85-p110 phosphatidyl 3′-kinase stimulates DNA synthesis by Ras- and p70 S6 kinase-dependent pathways
29. Molecular signals in anti-apoptotic survival pathways
30. Oncogenic kinase signalling
31. Effect of intravenous 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity
32. 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs
33. Cluster analysis and display of genome-wide expression patterns
34. Cancer cells, chemotherapy, and gene clusters
35. Systematic variation in gene expression patterns in human cancer cell lines
36. Phorbol ester effect on differentiation of human myeloid leukemia cell lines blocked at different stages of maturation
37. Exposure to TPA in vitro as an aid in the classification of blasts in human myelogenous and lymphoid leukemias
38. Acute undifferentiated leukemia: Induction of partial differentiation by phorbol ester
39. Differential effects of phorbol esters on normal myeloid precursors and leukemic cells
40. Transcriptional and post-transcriptional regulation of c-jun expression during monocytic differentiation of human myeloid leukemia cells
41. The role of jun and fos in 12-O-tetradecanoylphorbol-13-acetate induced hematopoietic differentiation
42. Expression of c-jun during macrophage differentiation of HL60 cells
43. Differential effects of phorbol ester on signaling and gene expression in human cells
44. Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal regulated kinase activation
45. Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer
46. Phase II study of bryostatin 1 in patients with relapsed multiple myeloma
47. A Phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
48. A Phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer
49. A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma
50. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow
51. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
52. A Phase I trial of bryostatin-1 in children with refractory solid tumors: A Pediatric Oncology Group study
53. Protein kinase C modulation and anticancer drug response
54. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways
55. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21(WAF1/CIP1/MDA6) in the reciprocal regulation of PKC activator-induced apoptosis and differentiation in human myelomonocytic leukemia cells
56. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937)